SCHEMBL13304680

SCHEMBL13304680

Bc1cnn2c(NCc3ccc[n+]([O-])c3)cc(-c3ccccc3)nc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 11/20 0.60
▸ CCNA2 P20248 2/20 0.60
▸ CCNA1 P78396 2/20 0.60
▸ GSK3B P49841 9/20 0.52
▸ CCNE1 P24864 5/20 0.51
▸ CDK9 P50750 5/20 0.46
▸ CDK5 Q00535 5/20 0.46
▸ CDK1 P06493 4/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ GSK3A P49840 2/20 0.43
▸ CDK7 P50613 2/20 0.43
▸ TAOK1 Q7L7X3 2/20 0.43
▸ CCNT1 O60563 1/20 0.43
▸ CCNT2 O60583 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ CCNK O75909 1/20 0.43
▸ CCNB2 O95067 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13305316 0.91 CDK2 (0.55) CDK2CCNA2CCNA1GSK3BCCNE1
SCHEMBL13305033 0.89 CDK2 (0.58) CDK2CCNA2CCNA1GSK3BCCNE1
SCHEMBL12952883 0.88 CDK2 (0.76) CDK2CCNA2CCNA1GSK3BCCNE1
SCHEMBL13304889 0.87 CDK2 (0.51) CDK2CCNA2CCNA1GSK3BCCNE1
SCHEMBL13304615 0.87 CDK2 (0.64) CDK2CCNA2CCNA1GSK3BCCNE1
SCHEMBL13305012 0.87 CDK2 (0.71) CDK2CCNA2CCNA1GSK3BCCNE1
SCHEMBL13304605 0.85 CDK2 (0.55) CDK2CCNA2CCNA1GSK3BCCNE1
SCHEMBL13304925 0.83 CDK2 (0.57) CDK2CCNA2CCNA1GSK3BCCNE1
SCHEMBL13304886 0.82 CDK2 (0.47) CDK2CCNA2CCNA1GSK3BCCNE1
SCHEMBL13146048 0.81 GSK3B (0.77) CDK2GSK3BCCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537116-B1 PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES SCHERING CORP (US) 2010-06-02 — — EP disclosed
Send feedback